| Drug General Information |
| Drug ID |
D0R1PZ
|
| Former ID |
DIB013949
|
| Drug Name |
F-15063
|
| Synonyms |
D2/D3 antagonists (psychosis/schizophrenia), Pierre Fabre
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Preclinical |
[1]
|
|---|
| Company |
Centre de Recherche Pierre Fabre
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C24H29NO2
|
| Canonical SMILES |
N(Cc1cc(ccc1)C1=CCCC1)CCOc1c2OC(Cc2ccc1)(C)C
|
| CAS Number |
CAS 936029-03-7
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
D(3) dopamine receptor |
Target Info |
Modulator |
|
|---|
| D(2) dopamine receptor |
Target Info |
Modulator |
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholism
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026348) |
|---|
